Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Spamming this board with VELA posts is just a way to disrupt the BB because they can’t get away with the same garbage they post on ADVFN boards because LSE site doesn’t let them away with the same garbage.
Shame they let posters change names to continue spamming though.
Bron still think the drawdown facility will be used first to give 6-12months runway to get CIZ test approved and then CIZ board will have fingers crossed for CDT to recover on them getting trial away for AZD asset, then CIZ can cash in for closer to Put option valuation.
No wonder PIPE holders took their $0.33cent per share profit when exercising g their right to take their money out. Emptied the CDT coffers.
“ We have incurred net losses since our inception. Our net losses were $2.3 million for the nine months ended September, 2023 and $4.9 million for Old Conduit for the year ended December 31, 2022. As of September 30, 2023, we had an accumulated deficit of $13.1 million. We do not expect to generate any significant revenues, if any, until we successfully complete adequate development of our first clinical asset. As of the date of this prospectus, our clinical assets are still in development and have not been approved by the FDA or any other regulatory body.
We have not yet demonstrated our ability to generate revenue, and we may never be able to produce revenues or operate on a profitable basis. We expect to experience operating losses and negative cash flow for the foreseeable future. Even if we are able to commercialize our technology, which may include licensing, we may never recover our research and development expenses.”
I’m here for the CIZ1b biomarker LDT and future developments or buyout.
85% and above would be decent at Stage 1.
90-95% would be ideal.
But at 95-98% for the CIZ1b LDT detecting lung cancer at stage 1, nothing comes close to touching that.
Not first but best with Breast cancer test being developed and if that is anywhere near 95% at stage 1 too then the number of lives saved will be enormous.
That’s part of the issue though Neil. Who or what are we waiting on. Last real update re mAbs was 5th July 2022. Nothing material since. Tweets saying “developing” or “creating” etc aren’t helping.
Is FairJourney Biologics CIZ are waiting on to produce additional mAbs for new uses?
“mAb supplier agreements extended to increase use case diversity
Work initiated to extend use case to breast cancer”
Or have FJB done their bit for the CIZ1b LDT and it’s over to TECH and CorePath to confirm assay optimisation?
“Monoclonal antibody ("mAb") to CIZ1B now in assay optimisation
mAb reporter protein developed and ready for test development “
There has to have been progress which is relevant to where CIZ currently are. In the bright side money isn't being wasted issuing RNS releases.
Looks like end of April for results ended December 2023 for anything. Unless there is the possibility of Options coming into play.
Dr. Tapolczay is scheduled to present on Wednesday, February 14, 2024, at 8:00 am EST/13:30 GMT, and will be participating in one-on-one investor meetings throughout the conference.
A live webcast of the presentation will be available on the Company Events section of the company's website at conduitpharma.com. A webcast replay can be accessed on the website and will remain available for 90 days.
1/2- In a report from @LungAmbition, titled: ‘Lung Cancer Screening: The Cost of Inaction, states that:
“Early detection represents the best chance to reduce the number of lives lost to lung cancer.”
#CancerDetection #LungCancer #SaveLives #NHS
2/2 - We are dedicated in our pursuit to advance early lung #cancer detection. We are creating a simple blood test that can detect the CIZ1B biomarker, which is highly associated with early-stage lung cancer. The tests will be cost-effective to produce and simple to use.
#CIZ
If 75% QoQ growth holds into Q4 then around 102,000 prescriptions. Tall order though. Fingers crossed it’s achieved.
Nothing since 10th August 2023. But tweeting “ @Cizzle is working hard to develop a clinical test for the CIZ1B biomarker which is highly associated with early-stage lung cancer”
Is it developed or not?
“ The next steps are to finalise standard production and operating protocols and to commence clinical trials that should lead to an accredited Laboratory Developed (LDT) test for launch initially in the USA. The Company will then extend that to other key markets and will extend its use through regulatory approval with the FDA in the USA, the EMA for a CE mark in Europe, the MHRA in the UK for UKCA approval, and with the appropriate regulatory groups elsewhere in the world including China.”
Occam - I used to hold here but no longer following the current board announcing on 2nd May 2023 - "Therefore, the Board has decided to evaluate over the coming weeks a range of financing options for the Company, including how Plant Health Care might access non-dilutive and strategic capital to support its growth ambitions. As part of this process, the Board intends to consult with shareholders as to whether AIM remains the right capital market for Plant Health Care to achieve its ambitions"
That destroyed any trust in what could have been a superb company. The dual listing, in my view, remains indicative of this Boards ambitions to delist from AIM and gain a full listing in the US. "
18/05/23 - This didnt inspire much confidence "Whilst there are various perspectives within the shareholder base with regards to the listing on AIM and there is a broad acceptance that the Company is currently under-valued, there is clearly a prevailing view that the Company should remain listed. Having considered the feedback in full, the Board is pleased to confirm, therefore, that the Company remains committed to its listing on AIM, including for any potential funding needs."
Also Scobie Ward has increased their holding (and influence) to 13.1% whilst Richard Griffiths has reduced their holding to 5.54%.
The current SP suggests I made the correct choice for me. Until there is a new board in place who are committed to growing this company as a UK listing its not for me. Still love the products and what the company as a whole are trying to achieve but my view is the current board care little for PI's and would think nothing of delisting from aim with zero thought or notice to PI's.
Be interesting to see if Richard Griffiths remains a seller and clears out fully from PHC.
Until there is a Board change or PHC's future listing is confirmed whether AIM or NASDAQ ill keep watching from the side.